Swedish Orphan Biovitrum

Company snapshot

Sobiは、希少疾患の患者さんとそのご家族の生活を改善するために、革新的な治療法を提供する国際的なバイオ医薬品企業です。 血液領域、免疫領域、スペシャリティケアを重点領域とし、この分野で革新的な治療法への持続的なアクセスを提供しています。 その日本法人であるSobi Japanは2020年6月に設立されました。 日本の希少・難治性疾患の患者さんの為に革新的な新薬をお届けし、笑顔で生活していただくことを願い、これからも日々挑戦し続けて参ります。

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Swedish Orphan Biovitrum. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Swedish Orphan Biovitrum.

1. Jun 8, 2026 Clinical update

   Sobi.BIVV001-003 — Phase 1

2. Jun 8, 2026 Clinical update

   Sobi.BIVV001-002 — Phase 3

3. Jun 8, 2026 Clinical update

   Sobi.PEGCET-201 — Phase 2

4. Jun 8, 2026 Clinical update

   Sobi.BIVV001-005 — Approved

5. Jun 8, 2026 Clinical update

   Sobi.BIVV001-004 — Approved

View all clinical trial activity →

• What is Swedish Orphan Biovitrum?

  Swedish Orphan Biovitrum is a pharma organization headquartered in Stockholm, JP. Primary therapeutic focus areas include Haemophilia A, Still's Disease, Juvenile Onset, Primary Myelofibrosis, Transplant-associated Thrombotic Microangiopathy (TA TMA). NovaPharmaNews links 7 clini

• Is Swedish Orphan Biovitrum publicly traded?

  Swedish Orphan Biovitrum appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Swedish Orphan Biovitrum develop or market?

  We link 12 drug profile(s) where Swedish Orphan Biovitrum is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/swedish-orphan-biovitrum-ab-publ#company-drugs.

• What are the latest developments for Swedish Orphan Biovitrum?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Swedish Orphan Biovitrum focus on?

  Swedish Orphan Biovitrum focuses on Haemophilia A, Still's Disease, Juvenile Onset, Primary Myelofibrosis based on our analysis of their pipeline programs and drug development activities.